Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms

作者: Kenichi Suda , Christopher J Rivard , Tetsuya Mitsudomi , Fred R Hirsch

DOI: 10.1080/14737140.2017.1355243

关键词:

摘要: ABSTRACTIntroduction: despite initial dramatic efficacy of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancer patients, emergence acquired resistance is almost inevitable. The T790M secondary mutation that accounts for ~50% now treatable with osimertinib. However, the remaining 50% patients who develop mechanisms other than mutation, cytotoxic chemotherapies are still standard care and novel treatment strategies urgently needed.Areas covered: In this review, we discuss current experimental clinical evidence to better overcome or prevent EGFR-TKIs cancers, focusing on non-T790M mechanisms.Expert commentary: There numerous resistant EGFR-TKIs, therefore, can be applied many these may reasonable useful practice. Although combination chemotherapy plus an EGFR-...

参考文章(87)
Kenichi Suda, Tetsuya Mitsudomi, Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity Archives of Toxicology. ,vol. 89, pp. 1227- 1240 ,(2015) , 10.1007/S00204-015-1524-7
Kyoko Otsuka, Akito Hata, Jumpei Takeshita, Chiyuki Okuda, Reiko Kaji, Katsuhiro Masago, Shiro Fujita, Nobuyuki Katakami, EGFR‑TKI rechallenge with bevacizumab in EGFR‑mutant non‑small cell lung cancer Cancer Chemotherapy and Pharmacology. ,vol. 76, pp. 835- 841 ,(2015) , 10.1007/S00280-015-2867-8
Kenneth S Thress, Cloud P Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J Carl Barrett, Pasi A Jänne, Geoffrey R Oxnard, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M Nature Medicine. ,vol. 21, pp. 560- 562 ,(2015) , 10.1038/NM.3854
Helena A. Yu, Shaozhou K. Tian, Alexander E. Drilon, Laetitia Borsu, Gregory J. Riely, Maria E. Arcila, Marc Ladanyi, Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain JAMA Oncology. ,vol. 1, pp. 982- 984 ,(2015) , 10.1001/JAMAONCOL.2015.1066
Samuel J. Klempner, Lyudmila A. Bazhenova, Fadi S. Braiteh, Petros G. Nikolinakos, Kyle Gowen, Claudia M. Cervantes, Juliann Chmielecki, Joel R Greenbowe, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Siraj M. Ali, Sai-Hong Ignatius Ou, Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI Lung Cancer. ,vol. 89, pp. 357- 359 ,(2015) , 10.1016/J.LUNGCAN.2015.06.021
Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Ikuo Sekine, Hideo Kunitoh, Kaoru Kubota, Tomohide Tamura, Yuichiro Ohe, Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. ,vol. 89, pp. 287- 293 ,(2015) , 10.1016/J.LUNGCAN.2015.06.016
Yi-Nan Liu, Tzu-Hua Chang, Meng-Feng Tsai, Shang-Gin Wu, Tzu-Hsiu Tsai, Hsuan-Yu Chen, Sung-Liang Yu, James Chih-Hsin Yang, Jin-Yuan Shih, IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer Oncotarget. ,vol. 6, pp. 10415- 10431 ,(2015) , 10.18632/ONCOTARGET.3389
Shinsuke Hashida, Hiromasa Yamamoto, Kazuhiko Shien, Yuichiro Miyoshi, Tomoaki Ohtsuka, Ken Suzawa, Mototsugu Watanabe, Yuho Maki, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Shinichiro Miyoshi, Shinichi Toyooka, Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib Cancer Science. ,vol. 106, pp. 1377- 1384 ,(2015) , 10.1111/CAS.12749
D. Planchard, Y. Loriot, F. André, A. Gobert, N. Auger, L. Lacroix, J.C. Soria, EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients Annals of Oncology. ,vol. 26, pp. 2073- 2078 ,(2015) , 10.1093/ANNONC/MDV319
Koh Furugaki, Junko Fukumura, Toshiki Iwai, Keigo Yorozu, Mitsue Kurasawa, Mieko Yanagisawa, Yoichiro Moriya, Kaname Yamamoto, Kenichi Suda, Hiroshi Mizuuchi, Tetsuya Mitsudomi, Naoki Harada, Impact of bevacizumab in combination with erlotinib on EGFR‐mutated non–small cell lung cancer xenograft models with T790M mutation or MET amplification International Journal of Cancer. ,vol. 138, pp. 1024- 1032 ,(2016) , 10.1002/IJC.29848